Back HCV Treatment

HCV Treatment

AASLD 2014: Sofosbuvir/Ledipasvir and AbbVie 3D Cure Most People with HCV Genotype 4

Sofosbuvir/ledipasvir (Harvoni) without ribavirin and AbbVie's 3D regimen (paritaprevir/ombitasvir plus dasabuvir) both produced high sustained virological response rates for patients with hepatitis C virus (HCV) genotype 4, according to a pair of studies presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.

alt

Read more:

AASLD 2014: Daclatasvir TRIO Regimen Has Good Cure Rates With or Without Cirrhosis

A 12-week oral regimen of daclatasvir, asunaprevir, and beclabuvir, with or without ribavirin, cured 86% to 90% of genotype 1 hepatitis C patients with cirrhosis in the Phase 3 UNITY-2 trial, while the TRIO regimen without ribavirin demonstrated similar sustained response rates for non-cirrhotics in UNITY-1, according to 2 late-breaking reports presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston. Findings suggest that ribavirin is still useful for some harder-to-treat patients.

alt

Read more:

AASLD 2014: Sofosbuvir/Ledipasvir Cures Nearly All Genotype 1 HIV/HCV Coinfected Patients

All but 1 participant treated with a coformulation of sofosbuvir and ledipasvir (Harvoni) achieved sustained virological response at 12 weeks post-treatment in a study looking at traditionally hard-to-treat HIV/HCV coinfected patients, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.

alt

Read more:

AASLD 2014: Sustained Response to HCV Treatment Reduces Mortality, Liver Cancer, Liver Transplants

People who achieve sustained virological response (SVR) when treated with interferon-based therapy for hepatitis C have a lower risk of death, are less likely to develop liver cancer, and need fewer liver transplants than those who were treated but not cured, according to results from a meta-analysis of more than 34,000 patients presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.

alt

Read more:

FDA Approves Simeprevir + Sofosbuvir Combination for Hepatitis C

The U.S. Food and Drug Administration (FDA) this week announced additional approval of interferon-free oral therapy for chronic hepatitis C combining Janssen's HCV protease inhibitor simeprevir (Olysio) plus Gilead Sciences' HCV polymerase inhibitor sofosbuvir (Sovaldi), both of which were approved separately in late 2013.

alt

Read more: